Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Andrei R. Shustov,Steven M. Horwitz,Jasmine Zain,Manish R Patel, Sanjay Goel, Lubomir Sokol,Funda Meric-Bernstam,Geoffrey Shapiro,Sunita Dwivedy Nasta,Murali Janakiram,David M Weinstock,Ronald Korn,Marie Payton,D. Allen Annis,Dawn Pinchasik,Manuel Aivado,Amitkumar Mehta

Blood（2018）

引用 4|浏览1

暂无评分

摘要

Background: Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of NHL with poor prognosis. Frontline therapy yields a 50-70% overall response rate, but the majority of pts will relapse, which translates to poor overall survival.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要